Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
New Challenges in HPV Vaccination and Cancer Prevention
share announcement

New Challenges in HPV Vaccination and Cancer Prevention

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 8449

Special Issue Editors

Dr. Ignacio Zapardiel

E-Mail Website
Guest Editor
1. Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain
2. Obstetrics and Gynecology Department, UAM University, Madrid, Spain
3. Biomedical Research Institute – IdiPAZ, Madrid, Spain
Interests: gynecologic oncology; cervical cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Jesus de la Fuente Valero

E-Mail Website1 Website2
Guest Editor
Hospital Universitario Infanta Leonor, Madrid, Spain
Interests: HPV vaccines; cervical cancer; colposcopy

Special Issue Information

Dear Colleagues, 

The HPV vaccine has been established as the best option among prevention strategies to avoid the development of cervical cancer in women worldwide. During the last decade, we have observed a great evolution in HPV vaccines, such as the increase in HPV serotype coverage, but also in their strategic implementation expanding to more extreme age ranges. Investigating the challenges associated with therapeutic HPV vaccines may open a new horizon in the fight against cervical cancer. In parallel, knowledge about the etiopathogenesis, transmission mechanisms, and evolution of the disease have been changing in recent years as well. All these research lines and new findings make this Special Issue an opportunity to communicate promising research lines, new concepts, results of immunization on different populations (based on age, previous surgical treatments, immunosuppressed patients, etc.), and every single development related to HPV vaccines.

We hope all authors and researchers consider this opportunity to publish their work in this Vaccines journal.

Dr. Ignacio Zapardiel
Dr. Jesus de la Fuente Valero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HPV
  • vaccines
  • cervical cancer
  • prevention
  • therapeutic vaccines

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

13 pages, 2378 KiB  
Article
Lineage Replacement and Genetic Changes of Four HR-HPV Types during the Period of Vaccine Coverage: A Six-Year Retrospective Study in Eastern China
by Wenjie Qu, Chen Hua, Yaping Wang, Yan Wang, Lu Zhang, Zhiheng Wang, Wenqian Shi, Fang Chen, Zhiyong Wu, Qian Wang, Lu Lu, Shibo Jiang, Long Sui and Yanyun Li
Vaccines 2024, 12(4), 411; https://doi.org/10.3390/vaccines12040411 - 12 Apr 2024
Viewed by 351
Abstract
Objective: This study aimed to provide clinical evidence for lineage replacement and genetic changes of High-Risk Human Papillomavirus (HR-HPV) during the period of vaccine coverage and characterize those changes in eastern China. Methods: This study consisted of two stages. A total of 90,583 [...] Read more.
Objective: This study aimed to provide clinical evidence for lineage replacement and genetic changes of High-Risk Human Papillomavirus (HR-HPV) during the period of vaccine coverage and characterize those changes in eastern China. Methods: This study consisted of two stages. A total of 90,583 patients visiting the Obstetrics and Gynecology Hospital of Fudan University from March 2018 to March 2022 were included in the HPV typing analysis. Another 1076 patients who tested positive for HPV31, 33, 52, or 58 from November 2020 to August 2023 were further included for HPV sequencing. Vaccination records, especially vaccine types and the third dose administration time, medical history, and cervical cytology samples were collected. Viral DNA sequencing was then conducted, followed by phylogenetic analysis and sequence alignment. Results: The overall proportion of HPV31 and 58 infections increased by 1.23% and 0.51%, respectively, while infection by HPV33 and 52 decreased by 0.42% and 1.43%, respectively, within the four-year vaccination coverage period. The proportion of HPV31 C lineage infections showed a 22.17% increase in the vaccinated group, while that of the HPV58 A2 sublineage showed a 12.96% increase. T267A and T274N in the F-G loop of HPV31 L1 protein, L150F in the D-E loop, and T375N in the H-I loop of HPV58 L1 protein were identified as high-frequency escape-related mutations. Conclusions: Differences in epidemic lineage changes and dominant mutation accumulation may result in a proportional difference in trends of HPV infection. New epidemic lineages and high-frequency escape-related mutations should be noted during the vaccine coverage period, and regional epidemic variants should be considered during the development of next-generation vaccines. Full article
(This article belongs to the Special Issue New Challenges in HPV Vaccination and Cancer Prevention)
►▼ Show Figures

Figure 1

12 pages, 289 KiB  
Article
HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
by Carla Henere, Aureli Torné, Anna Llupià, Marta Aldea, Cristina Martí, Ariel Glickman, Adela Saco, Lorena Marimon, Carolina Manzotti, Natalia Rakislova, Jaume Ordi and Marta del Pino
Vaccines 2022, 10(6), 887; https://doi.org/10.3390/vaccines10060887 - 01 Jun 2022
Cited by 7 | Viewed by 1782
Abstract
Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against [...] Read more.
Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-treatment HSIL. A second unanswered question is whether the vaccine has any effect in women with persistent HPV after treatment. We aimed to address these questions in a study of 398 women undergoing excisional treatment from July 2016 to December 2019. Vaccination was funded and offered to all women undergoing treatment. A total of 306 women (76.9%) accepted HPV vaccination (vaccinated group): 113 (36.9%) received the first dose before excision and 193 (63.1%) after the procedure. A total of 92 women (23.1%) refused the vaccine (non-vaccinated group). Women vaccinated before treatment showed a lower rate of post-treatment HSIL compared with non-vaccinated women (0.9% vs. 6.5%; p = 0.047). Among women with persistent HPV infection after treatment, those who had received the vaccine showed a lower prevalence of post-treatment HSIL than non-vaccinated women (2.6% vs. 10.5%; p = 0.043). In conclusion, this study shows that HPV vaccination before treatment reduces the prevalence of post-treatment HSIL and suggests that vaccination might even benefit women with persistent HPV after treatment. Full article
(This article belongs to the Special Issue New Challenges in HPV Vaccination and Cancer Prevention)

Review

Jump to: Research, Other

16 pages, 1499 KiB  
Review
Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?
by Giovanna Milano, Giovanni Guarducci, Nicola Nante, Emanuele Montomoli and Ilaria Manini
Vaccines 2023, 11(6), 1060; https://doi.org/10.3390/vaccines11061060 - 04 Jun 2023
Cited by 3 | Viewed by 4170
Abstract
Background and aim: Human papillomavirus (HPV) is sexually transmitted, one of the three most common sexually transmitted infections (STIs) in both males and females, and the most common viral STI. A crucial public health strategy to protect people against HPV is vaccination, which [...] Read more.
Background and aim: Human papillomavirus (HPV) is sexually transmitted, one of the three most common sexually transmitted infections (STIs) in both males and females, and the most common viral STI. A crucial public health strategy to protect people against HPV is vaccination, which has shown its effectiveness in preventing HPV-related diseases. Presently, three types of vaccines are available (bivalent, quadrivalent, and nonvalent), and they all target the two most oncogenic virus genotypes (HPV 16 and 18). In recent years, the need to implement vaccination programmes that include all genders has been discussed in order to achieve herd immunity against HPV. To date, only a few countries have included young males in their vaccination programmes. Thus, our objective with this review is to provide an overview of the epidemiology of HPV and HPV prevention strategies and report the latest findings from the scientific literature. Full article
(This article belongs to the Special Issue New Challenges in HPV Vaccination and Cancer Prevention)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

7 pages, 844 KiB  
Opinion
Efficacy of HPV Vaccination Regarding Vulvar and Vaginal Recurrences in Previously Treated Women: The Need for Further Evidence
by Angela Bechini, Andrea Moscadelli, Beatrice Velpini, Benedetta Bonito, Paolo Orlando, Pasqua Putignano, Silvano Posi, Lorenzo Stacchini, Paolo Bonanni and Sara Boccalini
Vaccines 2023, 11(6), 1084; https://doi.org/10.3390/vaccines11061084 - 09 Jun 2023
Cited by 1 | Viewed by 1532
Abstract
Vulvar and vaginal cancers are relatively rare cancers, but their incidence is increasing worldwide. Overall, 78% of vaginal cancers and 25% of vulvar cancers are associated with Human papillomavirus (HPV) infection. Immunization could be an option for the management of these cases. We [...] Read more.
Vulvar and vaginal cancers are relatively rare cancers, but their incidence is increasing worldwide. Overall, 78% of vaginal cancers and 25% of vulvar cancers are associated with Human papillomavirus (HPV) infection. Immunization could be an option for the management of these cases. We researched and assessed the evidence on the efficacy of HPV vaccination administered to women previously treated with surgery, radiotherapy, or chemotherapy with respect to the recurrence of vulvovaginal disease. From 2006 to November 2022, only one study evaluated the efficacy of HPV vaccination with respect to preventing vulvovaginal recurrences in treated women and showed that a quadrivalent HPV vaccine administered after the surgical treatment of vulvar high-grade squamous intraepithelial lesion (HSIL) can reduce vulvar recurrence of the disease. Therefore, the efficacy of HPV vaccination with respect to vulvovaginal recurrence is still an unexplored field. Further studies are needed to produce stronger evidence in order to appropriately support interventions to protect women’s health. Full article
(This article belongs to the Special Issue New Challenges in HPV Vaccination and Cancer Prevention)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop